Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18288634 | 0.93 | L3MBTL1 (0.56) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL2115851 | 0.93 | L3MBTL1 (0.56) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL2115854 | 0.93 | L3MBTL1 (0.56) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL2609692 | 0.92 | L3MBTL1 (0.54) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL18288674 | 0.85 | L3MBTL1 (0.47) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL29395178 | 0.84 | L3MBTL1 (0.45) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL19710848 | 0.82 | L3MBTL1 (0.44) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL18288645 | 0.82 | L3MBTL1 (0.57) | L3MBTL1RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL18566990 | 0.82 | L3MBTL1 (0.46) | L3MBTL1RAB9APOLBALDH1A1LMNA | |
| SCHEMBL18288643 | 0.81 | L3MBTL1 (0.58) | L3MBTL1RAB9APOLBNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | L3MBTL1 4164/4885RAB9A 2464/4885POLB 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.